Article Text

PDF

PWE-070 The Duodenal-Jejunal Bypass Sleeve (Endobarrier Gastrointestinal Liner) For Weight Loss and Treatment of Type Ii Diabetes
  1. S Patel1,
  2. D Hakim2,
  3. J Mason3,
  4. N Hakim4
  1. 1South Thames Foundation School, London, UK
  2. 2Royal College of Surgeons in Ireland, Dublin, Ireland
  3. 3Gastroenterology, Trafford General Hospital, Manchester
  4. 4Imperial College Healthcare NHS Trust, London, UK

Abstract

Introduction The Duodenal–jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) is an endoscopically and fluoroscopically inserted implant designed to aid weight loss, treat type II diabetes mellitus and improve the cardiovascular risk profile of subjects. We aimed to trial this device in a cohort of patients to assess efficacy.

Methods We implanted the EndoBarrier bypass sleeve into 57 patients from January 2011 to December 2012. The EndoBarrier is an impermeable fluoropolymer sleeve that is reversibly fixated to the duodenal bulb and extends 80cm into the small bowel, usually terminating in the proximal jejunum. It is implanted in the GI tract endoscopically to create a barrier between food and the wall of the intestine and to delay the mixing of digestive enzymes with food. It alters the activation of hormonal signals that originate in the intestine, thus mimicking the effects of a Roux-en-Y gastric bypass procedure without surgery.

Results Results showed weight loss in all patients, as well as lowering of blood sugar levels. Only 1 early device removal (due migration) occurred. There were no major postoperative side effects.

Conclusion Results confirm that the device reduces blood sugar levels and triggers weight loss. This non-permanent device implanted and removed endoscopically, controlled blood sugar and weight loss without the trauma of surgery. Clinical trials to date, involving more than 300 patients, have demonstrated significant weight loss and diabetes improvement with the Endobarrier. However, since this is a new procedure and due to the lack of data, it is not yet known if weight loss and diabetes benefits will persist.

Disclosure of Interest None Declared.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.